INTRODUCTION

Prostate cancer is the second most commonly diagnosed cancer in men and accounts for a great deal of morbidity and mortality in the male population [1, 2]. Current strategies to combat the disease include hormone therapy, surgery, radiation, and chemotherapy [1, 3-6]. Though effective at stalling the progression of the disease, these treatments do little to stop later stage metastatic prostate cancer, for which there is no standard of care outside of palliative support [7]. This suggests the need for new therapy techniques to combat the illness, such as the use of cancer vaccines and combined chemoimmunotherapy [8-10]. The concept of immunotherapy is not a relatively new idea; many trials have been conducted involving cancer vaccines aimed at eliciting a cytotoxic T lymphocyte (CTL) response with varying results [9, 11, 12]. These trials represent a great step toward applicable standards of care but they have failed to produce complete tumor clearance, the induction of a complete immune response, and the production of tumor specific memory T cells. The reason for this being the absence of therapies designed at invoking the HLA class II pathway of immune recognition.

While the importance of the class II pathway has been greatly appreciated [4, 13-16], it is poorly understood by most and is often overlooked when developing cancer vaccine strategies. This neglect represents the downfall of most tumor vaccine clinical trials as the cytotoxic response induced by CD8+ T lymphocytes is short-lived and unsustainable [17]. Activation of CD4+ T cells is required to stimulate and prolong CD8+ T cell activity, activate B cells, and to develop long-lasting tumor-specific memory T cells. CD4+ T cells also have the ability to directly kill tumor cells, to a much lesser degree than CD8+ T cells, through the release of cytotoxic cytokines and immunological stimulatory molecules [16, 18]. For these reasons, the class II pathway must be utilized for cancer vaccines to have a high clinical value. We and others have focused on developing strategies of using HLA class II inducing cancer vaccines, which will be highlighted in this review [4, 19-23].

Unlike the HLA-class I molecule which is conserved across almost every cell in the body, the class II molecule is mostly absent from somatic cells and in general is present on the surface of professional antigen presenting cells (APC) like B cells, macrophages, and dendritic cells (DC) [24]. Studies have shown that tumor cells express the class II molecule but at much lower levels than APCs, and this may be a factor in cancer cell immune evasion [25]. Our laboratory previously showed that prostate cancer cells express stable class II molecules which could be exploited for cancer vaccine development [4]. Our laboratory has also shown that the expression of class II proteins in prostate cancer cells can be upregulated through manipulation of the tumor growth condition and that the use of class II-restricted tumor Ags shows real promise for novel prostate cancer immunotherapy.

An important aspect of the class II pathway that can be exploited for cancer vaccine formation is the use of class II-restricted tumor derived antigens (Ags). Many of these Ags have been discovered for a variety of cancers [26-36], and viable prostate cancer tumor Ags do exist. In this review, we will mention some of these tumor Ags and describe their importance in cancer cell recognition by the immune system.

Keywords: Prostate cancer, HLA class II proteins, Hormones, GILT, Antigen processing and presentation, CD4+ T cells.
and how this can be exploited for effective immunotherapy when put in conjunction with cancer cell manipulation. This review will also highlight a recent case study that used combined chemoimmunotherapy to overcome hormone-refractory metastatic prostate cancer and the insight that this case gives to the improvement of future cancer vaccine strategies [8]. When taken together, this information proposes a viable guideline for the development of novel techniques for immunotherapy and the furthering of the field of cancer immunobiology.

HLA Class II Pathway for CD4+ T cell Recognition of Prostate Cancer Cells

The class II pathway is vital in the induction of a prolonged antitumor response [18, 37, 38]. And its importance cannot be overstated. The class II pathway is directly responsible for prolonged activation of CD8+ T cells, direct tumor killing via cytotoxic cytokines and the development of tumor specific memory T cells. As shown in Fig. (1A), when CD8 + T cells recognize the HLA class I molecule on the surface of prostate cancer cells, their cytotoxic effect can kill the tumor cells, reducing the overall tumor burden. However, this reaction is not sustained for a very long period, and the T cell begins to die off without the establishment of effective immunological memory. When the same tumor cells can present class II molecules on their surface for CD4+ T cell recognition in conjunction with the CD8 + T cell response, a more complete immune response occurs (Fig. 1B). The activated CD4+ cells T cells not only stimulate the CD8+ cells and prolong their activity, they also directly release cytokines and immune stimulatory molecules that further reduce the tumor burden. Vital to this interaction is the development of memory CD8 + T cells that will remain in circulation and respond to any resurgence of the tumor cells that might occur.

The class II Ag presentation pathway is quite different from the class I pathway in that tumor-derived proteins or Ags are endocytosed and processed by cells that express the class II molecule, resulting in the formation of novel shorter cancer peptides that can activate CD4+ T cells [17]. The HLA class II molecule expressed on the surface of professional APCs and some cancer cells is an alpha (α)/beta (β) heterodimer that is produced in the endoplasmic reticulum (ER). Inside of the ER another protein, the invariant chain (Ii), is also synthesized and bound to the class II molecule. This complex then moves from the ER through the trans-Golgi network to the endosomal and lysosomal compartments [22, 24, 39]. In these compartments, the Ii is removed and a chaperone molecule HLA-DM acts by selectively loading peptides into the class II binding groove [22]. The peptides that are loaded into the complex have been endocytosed by the cells and processed in the endosomal and lysosomal compartments by different cysteinyl and aspartyl cathepsins and reducing agents like Gamma-Interferon-inducible Lysosomal Thiol reductase (GILT), which prostate cancer
cells lack [4]. Once the peptide has been properly cut and folded into a functional ligand, it is loaded onto the class II binding groove. The entire complex is then moved to the cell’s surface and is presented to CD4+ T cells [20, 40]. Unlike tumor cells, APCs express costimulatory molecules such as CD80 and CD86 that enhance the T cell Receptor (TcR)-ligand complex interaction [23]. The presentation of tumor-derived epitopes via the class II pathway is also important in terms of cross-presentation and/or bystander presentation by DC for activation of CD8+ T cells through CD4+ T cell stimulation [25].

**HLA Class II-restricted Prostate Cancer Ags and Peptides**

In association with the importance of the class II pathway in cancer vaccine studies, the discovery of tumor-associated Ags that can be exploited is of great importance and has been studied thoroughly [26-36, 41]. We have previously outlined the importance of new epitope discovery as it applies to improved strategies for immunotherapy in cancer, autoimmunity, and infectious disease [17]. Many tumor-associated Ags have been discovered in various cancer types, with the majority being restricted to CD8+ T cell recognition. Stated earlier in this review, the strides made in CTL inducing cancer vaccines have provided a good foundation for improved prostate cancer therapy. Lacking in these advances is the induction of the class II pathway. One reason for this is the relatively small number of class II-restricted tumor-associated Ags discovered. In order to induce the HLA class II pathway tumor proteins must be unique in structure and sequence in order to bind with the class II binding groove [14, 42]. Also, many times peptides must be processed by professional APCs in order to bind to the class II complex and interact with TcR on CD4+ T cells [42, 43]. There are many Class II-restricted tumor Ags that have been discovered, but prostate cancer remains an area with few viable tumor Ags identified, a short list of which can be found in Table 1 [34, 44, 45].

<table>
<thead>
<tr>
<th>Prostate Cancer Ags</th>
<th>Class II-restricted epitopes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate Specific Antigen (PSA)</td>
<td>PSA49-63 (ILLAGMILFMIPEDTG)*</td>
</tr>
<tr>
<td>PSA</td>
<td>PSA64-78 (QVQVSHSPHPLYD)</td>
</tr>
<tr>
<td>Prostatic Acid Phosphatase (PAP)</td>
<td>PAP133-152 (NPILLWQPIPVHTVPSEDQ)</td>
</tr>
<tr>
<td>PAP</td>
<td>PAP173-192 (KEEFQKRLHPYKDIAATLG)</td>
</tr>
<tr>
<td>Prostate Specific Membrane Antigen (PSMA)</td>
<td>PSMA17 (RPRWLCAGALVLAGGFLFGF)</td>
</tr>
<tr>
<td>PSMA</td>
<td>PSMA120 (WKEFGLDSVELAHYD)</td>
</tr>
<tr>
<td>PSMA</td>
<td>PSMA196 (GKVFRGKKVNAQLA)</td>
</tr>
<tr>
<td>PSMA</td>
<td>PSMA459 (NYTLRVDCTPLMYS)</td>
</tr>
<tr>
<td>PSMA</td>
<td>PSMA376 (VAQVRGMVFMVSLNFPFD)</td>
</tr>
<tr>
<td>PSMA</td>
<td>PSMA390 (RQIYVAAFTQVAAS)</td>
</tr>
</tbody>
</table>

Table 1. Some of the known HLA class II-restricted tumor derived Ags and peptides from prostate Cancer Cells.

*1 indicates that M is substituted for H.
class II-restricted prostate cancer Ags an important term, immunodominance, must first be properly defined to set a guideline for tumor epitope generation. Immunodominance refers to the ability of the immune system to modulate and focus T cell responses to a select number of epitopes [17]. The immune system does not respond equally to each and every prostate tumor Ag synthesized, and more importantly many epitope sequences of tumor Ags work against the immune system by inducing tolerance and aiding in immune avoidance. By discovering the immunodominant epitope segment of a known prostate tumor Ag like PSA, immune avoidance can be overcome and the efficiency of a tumor vaccine would be greatly improved. Immunodominant peptides are also preferential for tumor vaccines as they generally act as the best ligands at interacting with the TcR of CD4+ T cells [44]. Investigation into exploiting these and other prostate tumor Ags for class II-restricted Ag presentation will advance the clinical benefit of immunotherapy of prostate cancer.

**Ag Processing and Presentation in Prostate Cancer Cells**

Ag processing and presentation as performed by professional APCs has been described in this review. What has yet to be mentioned is how prostate cancer cells differ from APCs and how this affects possible cancer vaccine strategies. One important characteristic that prostate cancer cells lack is the presence of GILT in endosomal and lysosomal compartments, altering the Ag processing capability of prostate cancer cells. Without GILT, the activity of cathepsins may decrease and the processing of viable tumor epitopes for class II presentation is decreased [20, 46]. Our recent studies have shown that melanoma cells transfected with GILT may upregulate costimulatory molecules like CD80 and CD86, improving class II-ligand complex and TcR interactions (unpublished data). GILT has also been shown to be vital in the reduction of cysteinylation peptides for proper Ag presentation; a quality that when absent, renders cancer cells that express non-reduced peptides muted as they may not activate T cells [42]. With this in mind, if prostate cancer cells could be modified to express GILT and other costimulatory molecules, then Ag processing and presentation via prostate cancer cells could be restored to near professional APC levels. The question left to answer being, do prostate cancer cells express viable class II molecules on their surface that can be exploited?

For a long time the accepted belief was that cancer cells did not express any class II on their surface as a means for immune avoidance. Recent discoveries by our laboratory and others have shown that some cancer cells do express functional HLA class II molecules on their surface that can be exploited for cancer vaccine strategies [47, 48]. Our laboratory has shown that prostate cancer cells express some components of the class II pathway, and that the expression of stable class II dimers can be induced by manipulating growth conditions, mainly by adding hormones to the culture condition of prostate cancer cells [4]. In the study performed, our laboratory manipulated the culture conditions of various prostate cancer cells and evaluated surface class II expression through Western blot analysis [4]. The results showed that prostate cancer cell lines (PC-3 and CWR22Rv1) expressed detectable levels of DRα and DRβ molecules when cultured in media rich in hormones (progesterone, testosterone, cortisol, corticosterone, triiodothyronine, and thyroxine). More importantly, stable class II DRββ dimer expression was shown. This finding raises the possibility that prostate cancer cells could be used as APCs for direct presentation of self Ags for CD4+ T cell stimulation. Prostate cancer cells alone are poor APCs and express very low levels of the class II molecules. When cultured in normal culture media (e.g., RPMI + calf serum or FBS), no detectable upregulation of class II molecules is seen and Ag presentation capability is minimally changed (Fig. 2). When the prostate cancer cells are incubated in the hormone rich media (e.g., RPMI + cosmic calf serum), class II-transactivator (CIITA) as well as stable ββ dimer and the Ag presenting capability of the prostate cancer cell is increased. Further improving the Ag processing and presentation of the prostate cancer cells is the upregulation of GILT in the prostate cancer cells, resulting in an increase of accessory molecules that aid in T cell recognition (Fig. 2). This data is important to note as it implies that through manipulation of the tumor environment hormone levels, and the induction of GILT, prostate cancer cells can express functional class II molecules that are capable of activating CD4+ T cells [4].

Our laboratory is not the only group researching the potential for class II directed cancer vaccines, Ostrand-Rosenberg et al have made great contributions to the study and have discovered some important characteristics of the class II pathway as it relates to cancer vaccine development [22, 23, 25]. Importantly, they claim that the tumor peptides derived by APCs may be immunogenic, but for the most part the patient becomes tolerized to the tumor peptides and no reactive CD4+ T cells are produced [22]. So, Ag presentation of tumor derived peptides that are synthesized in the absence of Ii represent a unique subset of peptides that may be able to overcome the induced tolerance seen [22]. They also contest that Ii negative class II-expressing cells are significantly better activators of tumor-reactive CD4+ T cells. By creating novel peptides, a diverse repertoire of CD4 + T cells could be activated resulting in a better immune response and an improved prophylactic benefit [22]. This phenomenon may not hold true for every tumor-derived epitope, but it does open up the field of class II vaccine candidates and it also presents a novel mechanism for avoiding T cell tolerance [49]. We have recently demonstrated that HLA-DM-negative cells preferentially present self Ag (e.g., collagen II peptide) to stimulate CD4+ T cells [19]. Coupling these two discoveries together, a concept that evolves is the existence of a DM-/Ii- class II pathway in cancer cells and that DM-/Ii- cancer cells are capable of inducing antitumor immune responses and avoiding T cell tolerance [19, 49]. These findings should be looked at as reference points for future class II-specific cancer vaccine trials.

**Future Directions for Improved Cancer Vaccination and Therapy**

Currently, immunotherapy does exist to treat prostate cancer but the results have been mixed [3, 5, 7, 11, 50-52]. The most common mode of therapy being delivery of prostate cancer peptides loaded on DC [8, 53]. Recent data suggest that more than four hundred prostate cancer patients have been treated with some form of DC loaded cancer vac-
cines, with a respectable two-thirds showing tumor specific immune responses [8]. Of this population, about half experienced a detectable clinical response to the therapy, further increasing the role for immunotherapy as a future standard of care [8]. Current studies suggest that complete tumor clearance by cancer vaccines alone is unlikely to occur, but that this does not have to happen for some clinical benefit to be gained [7, 8]. Furthermore, reducing the tumor burden and returning a patient back to a state of quiescence between the immune system and the cancer cells could greatly help the prognosis of metastatic cancer patients [8]. A recent case study performed at the Institute of Immunology in Prague highlighted a patient with hormone-refractory metastatic prostate cancer who was successfully treated with combined chemoimmunotherapy [8]. After the patient showed no response to current standards of care (irradiation and chemotherapy), the patient was enrolled in a new therapy that involved regular vaccinations with DC loaded with killed LnCap prostate cancer cells combined with palliative chemotherapy with docetaxel in alternating administration [8]. The study showed that noticeable cancer cell-specific immune responses were detectable from the DC-based vaccine therapy and the patient showed marked improvement in the clinical and laboratory setting as measured by the decrease of serum PSA levels by 90%, and at the time of publication, the patient remained in good clinical status [8]. This case study illustrates the benefit of combination chemoimmunotherapy at improving the clinical outcome of patient who had seemingly no viable option to combat the disease. This represents a new mechanism for improvement of current immunotherapy by adding alternating chemotherapy sessions to further reduce tumor burden. Case studies such as this one continue to show the validity of immunotherapy for treatment of prostate cancer. If these means of treatment could be improved to include class II activation through restricted tumor epitopes and improved class II processing by prostate cancer cells through tumor environment modification, then a new gold standard for cancer vaccine treatment could be established.

CONCLUSIONS

As mentioned in this review, the importance of the HLA class II pathway in developing more effective strategies for cancer vaccines must not be overlooked. Without eliciting a CD4+ T cell response, immunotherapy will never create a prolonged CTL response or develop long-lasting tumor-specific memory cells [4, 22, 42]. In this review, we also illustrated some of the discoveries made in class II vaccine strategies involving Ii and in class II-restricted prostate cancer Ags [22, 23, 36]. Also mentioned was how prostate cancer cells can be modified to express detectable levels of the class II dimer on their surface needed for CD4+ T cell recognition [4]. This review also highlighted a case study in which combined chemoimmunotherapy using alternating sessions of DC-based prostate cancer vaccinations and pal-
liative docetaxel therapy resulted in the improved clinical outcome of a patient with hormone-refractory metastatic prostate cancer [8]. These advances in the understanding of prostate cancer class II-processing and presentation will further expand this area of targeting tumors by immune cells. In all, this review provides a framework for the continued improvement of new prostate cancer immune therapy strategies.

ACKNOWLEDGEMENTS

This work was supported by grants from the Leukemia and Lymphoma Society (#3024) and National Institutes of Health (CA129560) to A.H.

LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>TcR</td>
<td>T cell Receptor</td>
</tr>
<tr>
<td>GILT</td>
<td>Gamma-Interferon-inducible Lysosomal Thiol reductase</td>
</tr>
<tr>
<td>PAP</td>
<td>Prostatic Acid Phosphatase</td>
</tr>
<tr>
<td>PSA</td>
<td>Prostate Specific Antigen</td>
</tr>
<tr>
<td>PSMA</td>
<td>Prostate Specific Membrane Antigen</td>
</tr>
<tr>
<td>PAP</td>
<td>Prostatic Acid Phosphatase</td>
</tr>
<tr>
<td>HLA</td>
<td>Human Leukocyte Antigen</td>
</tr>
<tr>
<td>PSA</td>
<td>Prostate Specific Antigen</td>
</tr>
<tr>
<td>PSMA</td>
<td>Prostate Specific Membrane Antigen</td>
</tr>
<tr>
<td>PAP</td>
<td>Prostatic Acid Phosphatase</td>
</tr>
</tbody>
</table>

REFERENCES


